Results 61 to 70 of about 3,001 (154)

Serious adverse events (SAE) reported for the period 1–5 months after the 2009 AS03-adjuvanted monovalent pandemic vaccine.

, 2013
Serious adverse events (SAE) reported for the period 1–5 months after the 2009 AS03-adjuvanted monovalent pandemic vaccine.
Louis Valiquette (186543), Chantal Bergeron (317019), Najwa Ouhoummane (250661), Manale Ouakki (317022), Anne McCarthy (176610), Julie Bettinger (317024), Gaston De Serres (156153), Judy Needham (317018), Kenna Sleigh (317021), Allison McGeer (196862), Shelly McNeil (317013), Brenda Coleman (317011), Ardith Ambrose (317017), Marie-Claude Gariépy (317009), Isabelle Rouleau (250665), Arlene Kallos (236339), Mélanie Benoît (317015), Cynthia Grenier (317020), Grant Stiver (317023)   +18 more
core   +1 more source

Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older

Human Vaccines & Immunotherapeutics, 2012
Objective: This study assessed the immunogenicity, long-term persistence of immune response and safety of a single dose of an A/California/07/2009 H1N1 pandemic influenza vaccine adjuvanted with AS03 (α-tocopherol and squalene based oil-in-water emulsion
Hideyuki Ikematsu, Kazuyoshi Tenjinbaru, Ping Li, Anuradha Madan, David Vaughn   +4 more
doaj   +1 more source

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, Volume 15, Issue 14, 10 April 2026.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

Identification of Mannose‐Capped‐Arabinomannan 101‐mer as a Potential Influenza Virus Vaccine Adjuvant

Advanced Science, Volume 13, Issue 21, 13 April 2026.
Well‐defined and synthetic mannose‐capped arabinomannan 101‐mer from Mycobacterium tuberculosis cell wall was identified as a potent influenza vaccine adjuvant, boosting the antibody response, realizing full protection and showing excellent safety. ABSTRACT Many natural bacterial components as adjuvants can activate the host immune system, but the ...
Yu‐Fang Zhang, Ruihong Xu, Jia Luo, Yuxin Ma, Guozhi Xiao, Ye Liu   +5 more
wiley   +1 more source

No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination

Vaccine: X, 2019
Influenza is a contagious respiratory illness caused by the influenza virus. The pandemic outbreak of influenza A H1N1 in 2009 (H1N1pdm09) gave us a unique opportunity to study humoral immune responses to a novel influenza vaccine strain.
Anders Madsen, Linda Azimi, Sarah Tete, Fan Zhou, Florian Krammer, Rebecca Jane Cox, Åsne Jul-Larsen   +6 more
doaj   +1 more source

Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19

Nature Communications, 2022
Here, the authors report results from a Phase 1 trial with an AS03-adjuvanted, plant-based virus-like particle displaying the spike protein of the ancestral SARS-CoV-2.
Philipe Gobeil, Stéphane Pillet, Iohann Boulay, Nathalie Charland, Aurélien Lorin, Matthew P. Cheng, Donald C. Vinh, Philippe Boutet, Robbert Van Der Most, François Roman, Maria Angeles Ceregido, Nathalie Landry, Marc-André D’Aoust, Brian J. Ward   +13 more
doaj   +1 more source

AS03-adjuvanted H5N1 vaccination induced early IP-10 and IL-6 serum cytokine and later protective immune responses relative to non-adjuvanted vaccine.

, 2017
Serum Antibody and cytokine responses by vaccine group (red: SV-AS03 (n = 10), blue: SV-PBS (n = 10)). (A) HAI and Nt antibody GMT and 95% CI at each time point by vaccine group; p-values are based on two-sided t-test on the log scale adjusting for ...
Heather Hill (3666856), Allison Galassie (694630), Kathryn M. Edwards (534416), Leigh M. Howard (694627), Laura E. Gordy (353375), Sebastian Joyce (353377), Shawn E. Levy (694633), Tara M. Allos (694631), Xinnan Niu (694628), Nripesh Prasad (694629), Travis L. Jensen (3666853), Johannes B. Goll (495915), Andrew J. Link (366977), C. Buddy Creech (748289), Kristen L. Hoek (694625), Parimal Samir (694626)   +15 more
core   +1 more source

Development of a Novel Polyleucine‐Based Immunopotentiator for Subunit Vaccines Against Group A Streptococcus

Small, Volume 22, Issue 22, 17 April 2026.
Self‐assembling amphiphilic peptide L15K6 is used as a novel immunoadjuvant for the development of a Group A Streptococcus vaccine. Robust antigen‐specific IgG responses are generated and manage to kill isolated strains of Group A Streptococcus. Cellular and bulk RNA sequencing data reveals that L15K6 regulates immune responses potentially through TLR ...
Lantian Lu, Jazmina L. Gonzalez Cruz, Rabina Giri, Yuexiao Zhang, Sahra Bashiri, Leslie C. Domínguez Cadena, Shuhang Li, Zeinab G. Khalil, Waleed M. Hussein, Jingwen Wang, Jolynn Kiong, Xuehan Lu, Jiahui Zhang, Miao Lu, Wenbin Huang, Wei Yang Kong, Ummey Jannatun Nahar, Prashamsa Koirala, Zhong Guo, Patricia Walden, Antje Blumenthal, Jakob Begun, Kirill Alexandrov, Istvan Toth, Rachel J. Stephenson, Mariusz Skwarczynski   +25 more
wiley   +1 more source

Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients [PDF]

, 2011
Responses to influenza vaccines are poorly characterized in immunocompromised patients. The goal of this study was to assess the efficacy of the AS03-adjuvanted influenza H1N1/A/09 vaccine in allogeneic hematopoietic stem cell transplant ...
Combescure, Christophe, Chalandon, Yves, Marrow Transplant Program,, Geneva University Hospitals H1N1 study group, Mohty, Bilal, B. Mohty, Nagy, Monika, M. Vukicevic, Levrat, Emmanuel, S. Grillet, Siegrist, Claire-Anne, Blood,, E. Levrat, L. Kaiser, Meier, Sara, S. Meier, Kaiser, Laurent, M. Nagy, Passweg, Jakob, Roosnek, Eddy, J. Passweg, E. Roosnek, Y. Chalandon, Grillet, Stephane, C.-A. Siegrist, Vukicevic, Marija, null null, Bel, Michael, M. Bel, C. Combescure, Meier S, Roosnek E, Bel M, Vukicevic M, Nagy M, Levrat E, Mohty B, Siegrist CA, Kaiser L, Passweg J, Combescure C, Chalandon Y, Grillet S   +42 more
core   +1 more source

Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants

npj Vaccines, 2021
Differences in innate immune ‘imprinting’ between vaccine adjuvants may mediate dissimilar effects on the quantity/quality of persisting adaptive responses.
Sonia Budroni, Francesca Buricchi, Andrea Cavallone, Patricia Bourguignon, Magalie Caubet, Vincent Dewar, Ugo D’Oro, Oretta Finco, Nathalie Garçon, Mohamed El Idrissi, Michel Janssens, Geert Leroux-Roels, Arnaud Marchant, Tino Schwarz, Pierre Van Damme, Gianfranco Volpini, Robbert van der Most, Arnaud M. Didierlaurent, Wivine Burny   +18 more
doaj   +1 more source